# Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

> **NCT06674915** · PHASE1 · COMPLETED · sponsor: **Chengdu Suncadia Medicine Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Complement Mediated Primary or Secondary Glomerular Diseases

## Interventions

- **DRUG:** HRS-5965 capsules

## Key facts

- **NCT ID:** NCT06674915
- **Lead sponsor:** Chengdu Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-26
- **Primary completion:** 2026-01-16
- **Final completion:** 2026-01-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674915, "Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06674915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*